A Phase I Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Dopamine D1 Receptor Partial Agonist, PF-06669571, ... View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2018-02-24

AUTHORS

Rachel Gurrell, Sridhar Duvvuri, Pengling Sun, Nicholas DeMartinis

ABSTRACT

Background and ObjectivesThere is an unmet medical need for additional treatment options for Parkinson’s disease. This was a Phase I, double-blind clinical trial assessing safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple doses of the novel dopamine D1 receptor partial agonist, PF-06669571, in subjects with idiopathic Parkinson’s disease on a stable dose of l-DOPA.MethodsSubjects received PF-06669571 (or matching placebo) titrated from 1 mg to 3 mg over 7 days. The primary pharmacodynamic endpoint was the change from baseline in Movement Disorder Society-Unified Parkinson’s Disease Rating Scale Part III total motor score at the pharmacodynamic time of maximum change from baseline on day 7.ResultsTwenty subjects were randomized and 19 completed the study. Maximum plasma concentrations (Cmax) of PF-06669571 were reached 3.35 and 3.19 h post-dose on day 1 and day 7. Geometric mean Cmax and area under the plasma concentration–time profile from time 0 to 24 h post-dose on day 7 were 92.51 ng/mL and 1626 ng·h/mL, respectively. The primary pharmacodynamic endpoint did not meet the pre-specified criteria for significant improvement; however, the criteria were met in a sensitivity analysis excluding data from a l-DOPA outlier (l-DOPA dose of 2550 mg/d). The most common adverse events (AEs) were nausea (experienced by 2 subjects each in the PF-06669571 and placebo groups). There were no permanent discontinuations or dose reductions due to AEs.DiscussionMultiple daily doses of PF-06669571 were safe and well tolerated with no notable safety concerns. The pharmacodynamic endpoint did not meet the pre-specified criteria for significant improvement.Clinicaltrials.gov identifierNCT02565628. More... »

PAGES

509-517

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s40261-018-0632-6

DOI

http://dx.doi.org/10.1007/s40261-018-0632-6

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1101210738

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/29478239


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1109", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Neurosciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Dopamine Agonists", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Dose-Response Relationship, Drug", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Double-Blind Method", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Levodopa", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Organic Chemicals", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Parkinson Disease", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Receptors, Dopamine D1", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Time Factors", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Pfizer Inc, Granta Park, CB21 6GP, Cambridge, UK", 
          "id": "http://www.grid.ac/institutes/grid.418566.8", 
          "name": [
            "Pfizer Inc, Cambridge, MA, USA", 
            "Pfizer Inc, Granta Park, CB21 6GP, Cambridge, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gurrell", 
        "givenName": "Rachel", 
        "id": "sg:person.01046751472.38", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01046751472.38"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Pfizer Inc, Cambridge, MA, USA", 
          "id": "http://www.grid.ac/institutes/grid.410513.2", 
          "name": [
            "Pfizer Inc, Cambridge, MA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Duvvuri", 
        "givenName": "Sridhar", 
        "id": "sg:person.01001070134.68", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01001070134.68"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Pfizer Inc, Cambridge, MA, USA", 
          "id": "http://www.grid.ac/institutes/grid.410513.2", 
          "name": [
            "Pfizer Inc, Cambridge, MA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sun", 
        "givenName": "Pengling", 
        "id": "sg:person.012313064520.10", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012313064520.10"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Pfizer Inc, Cambridge, MA, USA", 
          "id": "http://www.grid.ac/institutes/grid.410513.2", 
          "name": [
            "Pfizer Inc, Cambridge, MA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "DeMartinis", 
        "givenName": "Nicholas", 
        "id": "sg:person.0603502551.45", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0603502551.45"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/nrd3430", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025145286", 
          "https://doi.org/10.1038/nrd3430"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00415-014-7498-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024792493", 
          "https://doi.org/10.1007/s00415-014-7498-1"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2018-02-24", 
    "datePublishedReg": "2018-02-24", 
    "description": "Background and ObjectivesThere is an unmet medical need for additional treatment options for Parkinson\u2019s disease. This was a Phase I, double-blind clinical trial assessing safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple doses of the novel dopamine D1 receptor partial agonist, PF-06669571, in subjects with idiopathic Parkinson\u2019s disease on a stable dose of l-DOPA.MethodsSubjects received PF-06669571 (or matching placebo) titrated from 1\u00a0mg to 3\u00a0mg over 7\u00a0days. The primary pharmacodynamic endpoint was the change from baseline in Movement Disorder Society-Unified Parkinson\u2019s Disease Rating Scale Part III total motor score at the pharmacodynamic time of maximum change from baseline on day 7.ResultsTwenty subjects were randomized and 19 completed the study. Maximum plasma concentrations (Cmax) of PF-06669571 were reached 3.35 and 3.19\u00a0h post-dose on day 1 and day 7. Geometric mean Cmax and area under the plasma concentration\u2013time profile from time 0 to 24\u00a0h post-dose on day 7 were 92.51\u00a0ng/mL and 1626\u00a0ng\u00b7h/mL, respectively. The primary pharmacodynamic endpoint did not meet the pre-specified criteria for significant improvement; however, the criteria were met in a sensitivity analysis excluding data from a l-DOPA outlier (l-DOPA dose of 2550\u00a0mg/d). The most common adverse events (AEs) were nausea (experienced by 2 subjects each in the PF-06669571 and placebo groups). There were no permanent discontinuations or dose reductions due to AEs.DiscussionMultiple daily doses of PF-06669571 were safe and well tolerated with no notable safety concerns. The pharmacodynamic endpoint did not meet the pre-specified criteria for significant improvement.Clinicaltrials.gov identifierNCT02565628.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s40261-018-0632-6", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1100199", 
        "issn": [
          "1173-2563", 
          "1179-1918"
        ], 
        "name": "Clinical Drug Investigation", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "6", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "38"
      }
    ], 
    "keywords": [
      "primary pharmacodynamic endpoint", 
      "D1 receptor partial agonist", 
      "idiopathic Parkinson's disease", 
      "receptor partial agonist", 
      "pre-specified criteria", 
      "adverse events", 
      "pharmacodynamic endpoints", 
      "Parkinson's disease", 
      "day 7", 
      "double-blind clinical trial", 
      "partial agonist", 
      "phase I", 
      "common adverse events", 
      "notable safety concerns", 
      "additional treatment options", 
      "total motor score", 
      "geometric mean Cmax", 
      "maximum plasma concentration", 
      "plasma concentration-time profiles", 
      "unmet medical need", 
      "concentration-time profiles", 
      "stable dose", 
      "permanent discontinuation", 
      "motor score", 
      "daily doses", 
      "multiple doses", 
      "treatment options", 
      "mean Cmax", 
      "clinical trials", 
      "plasma concentrations", 
      "day 1", 
      "dose reduction", 
      "significant improvement", 
      "medical need", 
      "disease", 
      "time 0", 
      "tolerability", 
      "endpoints", 
      "pharmacodynamics", 
      "agonists", 
      "pharmacokinetics", 
      "safety concerns", 
      "doses", 
      "baseline", 
      "subjects", 
      "safety", 
      "discontinuation", 
      "ObjectivesThere", 
      "MethodsSubjects", 
      "Cmax", 
      "dose", 
      "maximum change", 
      "criteria", 
      "trials", 
      "DOPA", 
      "scores", 
      "days", 
      "improvement", 
      "changes", 
      "options", 
      "study", 
      "sensitivity analysis", 
      "background", 
      "reduction", 
      "events", 
      "concentration", 
      "need", 
      "profile", 
      "concern", 
      "data", 
      "time", 
      "area", 
      "analysis", 
      "outliers", 
      "novel dopamine D1 receptor partial agonist", 
      "dopamine D1 receptor partial agonist", 
      "PF-06669571", 
      "Movement Disorder Society-Unified Parkinson\u2019s Disease Rating Scale Part III total motor score", 
      "Disorder Society-Unified Parkinson\u2019s Disease Rating Scale Part III total motor score", 
      "Society-Unified Parkinson\u2019s Disease Rating Scale Part III total motor score", 
      "Parkinson\u2019s Disease Rating Scale Part III total motor score", 
      "\u2019s Disease Rating Scale Part III total motor score", 
      "Rating Scale Part III total motor score", 
      "Scale Part III total motor score", 
      "Part III total motor score", 
      "III total motor score", 
      "pharmacodynamic time", 
      "DOPA outlier", 
      "DiscussionMultiple daily doses", 
      "identifierNCT02565628"
    ], 
    "name": "A Phase I Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Dopamine D1 Receptor Partial Agonist, PF-06669571, in Subjects with Idiopathic Parkinson\u2019s Disease", 
    "pagination": "509-517", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1101210738"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s40261-018-0632-6"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "29478239"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s40261-018-0632-6", 
      "https://app.dimensions.ai/details/publication/pub.1101210738"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2021-11-01T18:33", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20211101/entities/gbq_results/article/article_785.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s40261-018-0632-6"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s40261-018-0632-6'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s40261-018-0632-6'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s40261-018-0632-6'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s40261-018-0632-6'


 

This table displays all metadata directly associated to this object as RDF triples.

237 TRIPLES      22 PREDICATES      131 URIs      121 LITERALS      20 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s40261-018-0632-6 schema:about N1642c7c9cb33442eb877a64472dfc49f
2 N506c2e87b03842bda15a66f81447cc73
3 N730b49b5b7834645a7a4b21f78dfabb7
4 N76d2506229be492bb08bbc77d8648ac2
5 N7d013b822bfc410bbb1ecb2505099e87
6 N8f04d92c32724014aec0a2e92407870d
7 N908bd9a7ac8448f6a7628166aa154e99
8 N99a347a1a2b84b73a8898008e9984d67
9 N9a1b01e7bf1b43a693f1a843ebc7bd00
10 N9d2dd642856442a08af78814d8dbb562
11 N9e6bee0a5841461fa098a885c10a5be2
12 Ne6dfcc9539cc4d3f8d0a19a3612696f7
13 Nf4c2336fc6e84938bdb7c8d3ea7147be
14 anzsrc-for:11
15 anzsrc-for:1109
16 schema:author Ncbf5af5cb92844938ec665a34ad3bf69
17 schema:citation sg:pub.10.1007/s00415-014-7498-1
18 sg:pub.10.1038/nrd3430
19 schema:datePublished 2018-02-24
20 schema:datePublishedReg 2018-02-24
21 schema:description Background and ObjectivesThere is an unmet medical need for additional treatment options for Parkinson’s disease. This was a Phase I, double-blind clinical trial assessing safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple doses of the novel dopamine D1 receptor partial agonist, PF-06669571, in subjects with idiopathic Parkinson’s disease on a stable dose of l-DOPA.MethodsSubjects received PF-06669571 (or matching placebo) titrated from 1 mg to 3 mg over 7 days. The primary pharmacodynamic endpoint was the change from baseline in Movement Disorder Society-Unified Parkinson’s Disease Rating Scale Part III total motor score at the pharmacodynamic time of maximum change from baseline on day 7.ResultsTwenty subjects were randomized and 19 completed the study. Maximum plasma concentrations (Cmax) of PF-06669571 were reached 3.35 and 3.19 h post-dose on day 1 and day 7. Geometric mean Cmax and area under the plasma concentration–time profile from time 0 to 24 h post-dose on day 7 were 92.51 ng/mL and 1626 ng·h/mL, respectively. The primary pharmacodynamic endpoint did not meet the pre-specified criteria for significant improvement; however, the criteria were met in a sensitivity analysis excluding data from a l-DOPA outlier (l-DOPA dose of 2550 mg/d). The most common adverse events (AEs) were nausea (experienced by 2 subjects each in the PF-06669571 and placebo groups). There were no permanent discontinuations or dose reductions due to AEs.DiscussionMultiple daily doses of PF-06669571 were safe and well tolerated with no notable safety concerns. The pharmacodynamic endpoint did not meet the pre-specified criteria for significant improvement.Clinicaltrials.gov identifierNCT02565628.
22 schema:genre article
23 schema:inLanguage en
24 schema:isAccessibleForFree false
25 schema:isPartOf N57bf10334e42427685e64aba3ac07633
26 Nbe3f33f7562e434a953d8c4c0df7034f
27 sg:journal.1100199
28 schema:keywords Cmax
29 D1 receptor partial agonist
30 DOPA
31 DOPA outlier
32 DiscussionMultiple daily doses
33 Disorder Society-Unified Parkinson’s Disease Rating Scale Part III total motor score
34 III total motor score
35 MethodsSubjects
36 Movement Disorder Society-Unified Parkinson’s Disease Rating Scale Part III total motor score
37 ObjectivesThere
38 PF-06669571
39 Parkinson's disease
40 Parkinson’s Disease Rating Scale Part III total motor score
41 Part III total motor score
42 Rating Scale Part III total motor score
43 Scale Part III total motor score
44 Society-Unified Parkinson’s Disease Rating Scale Part III total motor score
45 additional treatment options
46 adverse events
47 agonists
48 analysis
49 area
50 background
51 baseline
52 changes
53 clinical trials
54 common adverse events
55 concentration
56 concentration-time profiles
57 concern
58 criteria
59 daily doses
60 data
61 day 1
62 day 7
63 days
64 discontinuation
65 disease
66 dopamine D1 receptor partial agonist
67 dose
68 dose reduction
69 doses
70 double-blind clinical trial
71 endpoints
72 events
73 geometric mean Cmax
74 identifierNCT02565628
75 idiopathic Parkinson's disease
76 improvement
77 maximum change
78 maximum plasma concentration
79 mean Cmax
80 medical need
81 motor score
82 multiple doses
83 need
84 notable safety concerns
85 novel dopamine D1 receptor partial agonist
86 options
87 outliers
88 partial agonist
89 permanent discontinuation
90 pharmacodynamic endpoints
91 pharmacodynamic time
92 pharmacodynamics
93 pharmacokinetics
94 phase I
95 plasma concentration-time profiles
96 plasma concentrations
97 pre-specified criteria
98 primary pharmacodynamic endpoint
99 profile
100 receptor partial agonist
101 reduction
102 safety
103 safety concerns
104 scores
105 sensitivity analysis
106 significant improvement
107 stable dose
108 study
109 subjects
110 time
111 time 0
112 tolerability
113 total motor score
114 treatment options
115 trials
116 unmet medical need
117 ’s Disease Rating Scale Part III total motor score
118 schema:name A Phase I Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Dopamine D1 Receptor Partial Agonist, PF-06669571, in Subjects with Idiopathic Parkinson’s Disease
119 schema:pagination 509-517
120 schema:productId N15e0d0fc62114883a2ea30d770b94a87
121 N37c0bb30f36b424687eb3b08bbd46f4c
122 N5aa88eba07f3488cbc4708709d66bec1
123 schema:sameAs https://app.dimensions.ai/details/publication/pub.1101210738
124 https://doi.org/10.1007/s40261-018-0632-6
125 schema:sdDatePublished 2021-11-01T18:33
126 schema:sdLicense https://scigraph.springernature.com/explorer/license/
127 schema:sdPublisher N8480075059064bc69d95f49945040457
128 schema:url https://doi.org/10.1007/s40261-018-0632-6
129 sgo:license sg:explorer/license/
130 sgo:sdDataset articles
131 rdf:type schema:ScholarlyArticle
132 N15e0d0fc62114883a2ea30d770b94a87 schema:name pubmed_id
133 schema:value 29478239
134 rdf:type schema:PropertyValue
135 N1642c7c9cb33442eb877a64472dfc49f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
136 schema:name Levodopa
137 rdf:type schema:DefinedTerm
138 N356830bff22f43b9ada3abaa34a5e92c rdf:first sg:person.01001070134.68
139 rdf:rest N795cb9f8fb9f4694aa5b9ce50b86f01d
140 N37c0bb30f36b424687eb3b08bbd46f4c schema:name dimensions_id
141 schema:value pub.1101210738
142 rdf:type schema:PropertyValue
143 N506c2e87b03842bda15a66f81447cc73 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
144 schema:name Humans
145 rdf:type schema:DefinedTerm
146 N57bf10334e42427685e64aba3ac07633 schema:issueNumber 6
147 rdf:type schema:PublicationIssue
148 N5aa88eba07f3488cbc4708709d66bec1 schema:name doi
149 schema:value 10.1007/s40261-018-0632-6
150 rdf:type schema:PropertyValue
151 N730b49b5b7834645a7a4b21f78dfabb7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
152 schema:name Male
153 rdf:type schema:DefinedTerm
154 N76d2506229be492bb08bbc77d8648ac2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
155 schema:name Dopamine Agonists
156 rdf:type schema:DefinedTerm
157 N795cb9f8fb9f4694aa5b9ce50b86f01d rdf:first sg:person.012313064520.10
158 rdf:rest Nb0b4bb396f9d4ef88ae5978c6547f7e5
159 N7d013b822bfc410bbb1ecb2505099e87 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
160 schema:name Female
161 rdf:type schema:DefinedTerm
162 N8480075059064bc69d95f49945040457 schema:name Springer Nature - SN SciGraph project
163 rdf:type schema:Organization
164 N8f04d92c32724014aec0a2e92407870d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
165 schema:name Time Factors
166 rdf:type schema:DefinedTerm
167 N908bd9a7ac8448f6a7628166aa154e99 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
168 schema:name Organic Chemicals
169 rdf:type schema:DefinedTerm
170 N99a347a1a2b84b73a8898008e9984d67 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
171 schema:name Aged
172 rdf:type schema:DefinedTerm
173 N9a1b01e7bf1b43a693f1a843ebc7bd00 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
174 schema:name Double-Blind Method
175 rdf:type schema:DefinedTerm
176 N9d2dd642856442a08af78814d8dbb562 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
177 schema:name Receptors, Dopamine D1
178 rdf:type schema:DefinedTerm
179 N9e6bee0a5841461fa098a885c10a5be2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
180 schema:name Middle Aged
181 rdf:type schema:DefinedTerm
182 Nb0b4bb396f9d4ef88ae5978c6547f7e5 rdf:first sg:person.0603502551.45
183 rdf:rest rdf:nil
184 Nbe3f33f7562e434a953d8c4c0df7034f schema:volumeNumber 38
185 rdf:type schema:PublicationVolume
186 Ncbf5af5cb92844938ec665a34ad3bf69 rdf:first sg:person.01046751472.38
187 rdf:rest N356830bff22f43b9ada3abaa34a5e92c
188 Ne6dfcc9539cc4d3f8d0a19a3612696f7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
189 schema:name Parkinson Disease
190 rdf:type schema:DefinedTerm
191 Nf4c2336fc6e84938bdb7c8d3ea7147be schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
192 schema:name Dose-Response Relationship, Drug
193 rdf:type schema:DefinedTerm
194 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
195 schema:name Medical and Health Sciences
196 rdf:type schema:DefinedTerm
197 anzsrc-for:1109 schema:inDefinedTermSet anzsrc-for:
198 schema:name Neurosciences
199 rdf:type schema:DefinedTerm
200 sg:journal.1100199 schema:issn 1173-2563
201 1179-1918
202 schema:name Clinical Drug Investigation
203 schema:publisher Springer Nature
204 rdf:type schema:Periodical
205 sg:person.01001070134.68 schema:affiliation grid-institutes:grid.410513.2
206 schema:familyName Duvvuri
207 schema:givenName Sridhar
208 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01001070134.68
209 rdf:type schema:Person
210 sg:person.01046751472.38 schema:affiliation grid-institutes:grid.418566.8
211 schema:familyName Gurrell
212 schema:givenName Rachel
213 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01046751472.38
214 rdf:type schema:Person
215 sg:person.012313064520.10 schema:affiliation grid-institutes:grid.410513.2
216 schema:familyName Sun
217 schema:givenName Pengling
218 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012313064520.10
219 rdf:type schema:Person
220 sg:person.0603502551.45 schema:affiliation grid-institutes:grid.410513.2
221 schema:familyName DeMartinis
222 schema:givenName Nicholas
223 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0603502551.45
224 rdf:type schema:Person
225 sg:pub.10.1007/s00415-014-7498-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024792493
226 https://doi.org/10.1007/s00415-014-7498-1
227 rdf:type schema:CreativeWork
228 sg:pub.10.1038/nrd3430 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025145286
229 https://doi.org/10.1038/nrd3430
230 rdf:type schema:CreativeWork
231 grid-institutes:grid.410513.2 schema:alternateName Pfizer Inc, Cambridge, MA, USA
232 schema:name Pfizer Inc, Cambridge, MA, USA
233 rdf:type schema:Organization
234 grid-institutes:grid.418566.8 schema:alternateName Pfizer Inc, Granta Park, CB21 6GP, Cambridge, UK
235 schema:name Pfizer Inc, Cambridge, MA, USA
236 Pfizer Inc, Granta Park, CB21 6GP, Cambridge, UK
237 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...